Catherine Patte

Catherine Patte

Auto-generated profile, based on publicly available information

Catherine Patte

Institut Gustave-Roussy

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2001 in Blood
Verified
Journal Article
Closed access
CPC. Patte
C. Patte
This study was undertaken to show that a high survival rate can be obtained in B-cell (Burkitt and large B-cell) lymphoma and L3 leukemia with multiagent chemotherapy adapted to the tumor burden (stage, resection status, percentage of blasts in bone marrow, and central nervous system [CNS] involvement) and early response to chemotherapy, to investigate actual prognostic factors, and to see if large B-cell lymphoma can be treated with the same regimen as Burkitt lymphoma. Patients were classified into 3 risk groups. Group A (resected stage I and abdominal stage II) received 2 courses of vincristine, cyclophosphamide, doxorubicin, and prednisone. Group B (patients not eligible for groups A or C) received 5 courses of chemotherapy with, in addition, high-dose methotrexate, 3 g/m(2) over 3 hours; infusional cytarabine; and intrathecal (IT) methotrexate. Group C (patients with CNS involvement and acute lymphoblastic leukemia with at least 70% of blasts in bone marrow) received 8 courses with, in addition, high-dose methotrexate, 8 g/m(2); high-dose cytarabine; etoposide; and triple IT. Except in group A, treatment started with a prephase (COP, low-dose vincristine and cyclophosphamide). It was intensified for patients who did not respond to COP in group B and any patient with residual viable cells after the consolidation phase. A total of 561 patients were enrolled in the SFOP LMB89 protocol (July 1989-June 1996). Five-year survival is 92.5% (95% confidence interval [CI], 90%-94%) and event-free survival (EFS) 91% (95% CI, 89%-93%). EFS is 98% (95% CI, 90%-100%), 92% (95% CI, 89%-95%), and 84% (95% CI, 77%-90%) for group A, B, and C, respectively. In group B, multivariate analysis of prognostic factors showed that a lactate dehydrogenase level more than 2-fold the normal value, no response after COP, and age of at least 15 years were associated with a lower EFS. CNS involvement was the only prognostic factor in group C. (Blood. 2001;97:3370-3379)

28 November 2006 in Blood
Verified
Journal Article
Closed access
PDF file
CPCatherine Patte
Catherine Patte
AAAnne Auperin
Anne Auperin
MGMary Gerrard
Mary Gerrard
JMJean Michon
Jean Michon
RPRoss Pinkerton
Ross Pinkerton
MCMitchell S. Cairo
Mitchell S. Cairo
A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as “non-resected” stage I/II and CNS-negative advanced-stage III/IV (70% of cases). We performed the FAB/LMB96 trial to assess the possibility of reducing treatment in children/adolescents with intermediate-risk B-NHL without jeopardizing survival. “Early responding” patients (tumor response > 20% at day 7) were randomized in a factorial design between 4 arms, 2 receiving half-dose of cyclophosphamide in the second induction course with cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), methotrexate (COPADM) and 2 not receiving the maintenance course M1. A total of 657 patients were randomized (May 1996 to June 2001) and 637 were analyzed. The analysis showed no significant effect of any of the treatment reductions on EFS and survival. The 4-year EFS was 93.4% and 90.9% in the groups with full-dose and half-dose of cyclophosphamide (RR = 1.3, P = .40) and 91.9% and 92.5% in the groups with and without M1 (RR = 1.01, P = .98). There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell). Children/adolescents with intermediate-risk B-NHL who have an early response and achieve a complete remission after the first consolidation course can be cured with a 4-course treatment with a total dose of only 3.3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin.

1 May 2002 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
CPC Patte
C Patte
CSC Sakiroglu
C Sakiroglu
SAS Ansoborlo
S Ansoborlo
ABA Baruchel
A Baruchel
EPE Plouvier
E Plouvier
SPSociété Française D'Oncologie Pédiatrique
Société Française D'Oncologie Pédiatrique
Purpose To evaluate the frequency of metabolic complications and dialysis due to tumor lysis syndrome in patients with B-cell advanced-stage non-Hodgkin’s lymphoma (NHL) and L3 leukemia at initiation of chemotherapy including the use of urate-oxidase. Patients and methods Retrospective review of the clinical records of 410 patients with stage III and IV B-cell NHL and L3 leukemia treated in France and prospectively registered in the LMB89 protocol. Results During the first week of chemotherapy, only 34 of 410 patients recorded metabolic problems that included hypocalcemia (6.5 mg/dl) in 28 and elevation of creatinine ≥2 SD in 16. Six patients underwent dialysis for life-threatening problems and a seventh as a preventive measure. In the other 27 cases, metabolic problems were successfully resolved using urate-oxidase in combination with alkaline hyperhydration. Among the 410 patients, one case of hemolysis was reported and there was no severe allergic reaction to urate-oxidase. Conclusions Only 1.7% of patients in our study receiving urate-oxidase during their induction chemotherapy needed renal dialysis. Urate-oxidase was well tolerated, and used as prophylaxis and/or treatment of hyperuricemia and tumor lysis syndrome consistently gave a lower rate of renal and metabolic complications than in other series of similar patients.

1 December 2002 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
CPCatherine Patte
Catherine Patte

1 November 1997
Verified
Journal Article
Closed access
MBM C Baranzelli
M C Baranzelli
CPC Patte
C Patte
EBE Bouffet
E Bouffet
DCD Couanet
D Couanet
JHJ L Habrand
J L Habrand
CKC Kalifa
C Kalifa

15 January 2002 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CPC. Patte
C. Patte
ALA. Laplanche
A. Laplanche
ABA. I. Bertozzi
A. I. Bertozzi
ABA. Baruchel
A. Baruchel
DFD. Frappaz
D. Frappaz
JMJ. Michon
J. Michon
PURPOSE: To determine whether granulocyte colony-stimulating factor (G-CSF; lenograstim) decreases the incidence of febrile neutropenia after induction courses in treatment of childhood non-Hodgkin’s lymphoma (NHL). PATIENTS AND METHODS: Patients were randomized to receive (G-CSF+) or not receive (G-CSF−) prophylactic G-CSF, 5 μg/kg/d, from day 7 until an absolute neutrophil count ≥ 500/μL was sustained over 48 hours, after two consecutive induction courses of cyclophosphamide 1.5 or 3 g/m2, vincristine 2 mg/m2, prednisone 60 mg/m2/d × 5, doxorubicin 60 mg/m2, high-dose methotrexate 3 or 8 g/m2, and intrathecal injections (COPAD[M]) on protocols LMB89, LMT89, and HM91 of the French Society of Pediatric Oncology. RESULTS: One hundred forty-eight patients were assessable, 75 G-CSF+ and 73 G-CSF−. Although duration of neutropenia less than 500/μL was 3 days shorter in G-CSF+ patients (P = 10−4), incidence of febrile neutropenia (89% v 93% in the first course, 88% v 88% in the second course), durations of hospitalization and antimicrobial therapy, percentages of infections, mucositis, and transfusions were not significantly different. Although the percentage of G-CSF+ patients commencing the following course on day 21 was significantly higher (84% v 68% after the first and 57% v 38% after the second course; P < .05), the median delay between the two courses was only 1 day less in G-CSF+ patients (median delay after first COPAD(M), 19 v 20 days, P = .01; after second, 21 v 22 days, P = not significant). Remission and survival rates were similar in both arms. CONCLUSION: This study demonstrates that G-CSF did not decrease treatment-related morbidity, nor increase the dose-intensity in children undergoing COPAD(M) induction chemotherapy for NHL.